<version>
  <xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Quality Measures Clearinghouse (NQMC).</xmlsource>
  <section secid="560" ordby="10" name="General">
    <field fieldid="11" ordby="20" id="561" name="Title" type="text">
      <fieldvalue value="<div class=&quot;content_title&quot;>Non-Hodgkin lymphoma: percent of lymphoma patients who are 65 years old or older and receiving CHOP +/-R, prescribed prophylactic myeloid growth factor (MGF).</div>"/>
    </field>
    <field fieldid="1" ordby="30" id="562" name="Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>American Society of Hematology (ASH). Non-Hodgkin lymphoma measure set: measure specifications. Washington (DC): American Society of Hematology (ASH); 2017 Feb. 36 p. </td></tr></table>"/>
    </field>
  </section>
  <section secid="563" ordby="40" name="Measure Domain">
    <field fieldid="3025" ordby="50" id="564" name="Primary Measure Domain" type="picklist-one">
      <fieldvalue value="Clinical Quality Measures: Process"/>
    </field>
    <field fieldid="3026" ordby="60" id="565" name="Secondary Measure Domain" type="picklist-one">
      <fieldvalue value="Does not apply to this measure"/>
    </field>
  </section>
  <section secid="566" ordby="70" name="Brief Abstract">
    <field fieldid="34" ordby="80" id="567" name="Description" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This measure is used to assess the percent of lymphoma patients who are 65 years old or older and receiving CHOP +/-R (or any regimen with the same or higher doses of cyclophosphamide and doxorubicin and, thus, with an equivalent or higher potential for neutropenia), prescribed prophylactic myeloid growth factor (MGF) (filgrastim, filgrastim-sndz, tbo-filgrastim or pegfilgrastim). </p></div>"/>
    </field>
    <field fieldid="21" ordby="90" id="568" name="Rationale" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><em>Support (verbatim) from guidelines</em>:<br />
Prophylactic colony-stimulating factor (CSF) for patients with diffuse aggressive lymphoma aged 65 and older treated with curative chemotherapy (CHOP or more aggressive regimens) should be given to reduce the incidence of febrile neutropenia (FN) and infections (Smith et al., 2006). </p>
<p>Meta-analysis of controlled clinical trials on the prophylactic use of recombinant granulocyte CSFs has confirmed their effectiveness in reducing the risk of febrile neutropenia. Some concerns have been expressed that the combination of growth factors and topoisomerase II inhibitors may be associated with increased risk of acute leukemia; however, these data are controversial. Despite these caveats, the use of growth factors appears to be the best established strategy to improve treatment in this group of patients (National Comprehensive Cancer Network [NCCN], 2015). </p>
<p>The development of FN is a common dose-limiting toxicity of many single agent and combination chemotherapy regimens that is directly related to the intensity of the regimen. Clinical trial data of chemotherapy regimens that have an incidence of FN greater than 20% in chemotherapy-na&amp;iuml;ve patients are considered by the panel as high risk. It is emphasized that the type of chemotherapy regimen is only one component of the risk assessment and needs to be combined with patient risk factors for an estimation of the overall risk for FN. The most important risk factor for developing severe neutropenia is higher age, notably over 65 years, inpatients who receive full chemotherapy dose intensity (NCCN, 2016). </p>
<p>The NCCN, American Society of Clinical Oncology (ASCO), and European Organisation for Research and Treatment of Cancer (EORTC) guidelines all recognize a variety of special circumstances in which patients treated with relatively nonmyelosuppressive chemotherapy regimens are at high risk for FN due to bone marrow compromise or comorbidity. Prophylactic MGF is recommended for any patient considered at high risk, regardless of treatment intent (NCCN, 2016). </p>
<p>ASCO guidelines recommend using white cell-stimulating factors when the risk of FN secondary to a recommended chemotherapy regimen is approximately 20% and equally effective treatment programs that do not require white cell-stimulating factors are unavailable. Exceptions should be made when using regimens that have a lower chance of causing FN if it is determined that the patient is at high risk for this complication (as a result of age, medical history, or disease characteristics) (Schnipper et al., 2012).</p></div>"/>
    </field>
    <field fieldid="3500" ordby="100" id="569" name="Evidence for Rationale" type="citation">
      <fieldvalue value="<table><tr><td>American Society of Hematology (ASH). Non-Hodgkin lymphoma measure set: measure specifications. Washington (DC): American Society of Hematology (ASH); 2017 Feb. 36 p. </td></tr></table>"/>
      <fieldvalue value="<table><tr><td>National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: myeloid growth factors. Version 2.2016. Fort Washington (PA): National Comprehensive Cancer Network (NCCN); 2016 Jun 27. </td></tr></table>"/>
      <fieldvalue value="<table><tr><td>National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: older adult oncology. Version 2.2015. Fort Washington (PA): National Comprehensive Cancer Network (NCCN); 2015 May 14. </td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, Wollins DS. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012 May 10;30(14):1715-24. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22493340&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006 Jul 1;24(19):3187-205. [128 references] <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16682719&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
    </field>
    <field fieldid="3022" ordby="110" id="570" name="Primary Health Components" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Non-Hodgkin lymphoma (NHL); chemotherapy regimen; CHOP +/-R; cyclophosphamide; doxorubicin; neutropenia; prophylactic myeloid growth factor (MGF); filgrastim; filgrastim-sndz; tbo-filgrastim; pegfilgrastim; elderly</p></div>"/>
    </field>
    <field fieldid="23" ordby="120" id="571" name="Denominator Description" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The number of lymphoma patients in your selection:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Who are greater than or equal to 65 years old
    <p>AND</p>
    </li>
    <li>Treated with CHOP +/-R (or any regimen with the same or higher doses of cyclophosphamide and doxorubicin and, thus, with an equivalent or higher potential for neutropenia) </li>
</ul>
<p>See the related &quot;Denominator Inclusions/Exclusions&quot; field.</p></div>"/>
    </field>
    <field fieldid="24" ordby="130" id="572" name="Numerator Description" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The number of lymphoma patients in your selection:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Who are greater than or equal to 65 years old
    <p>AND</p>
    </li>
    <li>Treated with CHOP +/-R (or any regimen with the same or higher doses of cyclophosphamide and doxorubicin and, thus, with an equivalent or higher potential for neutropenia)
    <p>AND</p>
    </li>
    <li>Received prophylactic filgrastim, filgrastim-sndz, tbo-filgrastim or pegfilgrastim </li>
</ul>
<p>See the related &quot;Numerator Inclusions/Exclusions&quot; field.</p></div>"/>
    </field>
  </section>
  <section secid="573" ordby="140" name="Evidence Supporting the Measure">
    <field fieldid="3027" ordby="150" id="574" name="Type of Evidence Supporting the Criterion of Quality for the Measure" type="picklist-choice">
      <fieldvalue value="A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence"/>
      <fieldvalue value="One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal"/>
    </field>
    <field fieldid="3501" ordby="160" id="575" name="Additional Information Supporting Need for the Measure" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><em>Guideline statements on gap</em>:<br />
There remains wide variation in the appropriate use of granulocyte colony-stimulating factors (G-CSFs) for primary prophylaxis of febrile neutropenia (FN) in clinical practice. This variation from guideline standards results in increased use of these costly agents when the risk of FN is low. Conversely, the risk and morbidity of FN are increased when these agents are withheld as primary prophylaxis, contrary to guidelines (Schnipper et al., 2012).</p>
<p>Neutropenia and resulting FN can be induced by myelosuppressive chemotherapy. FN in turn is a major dose-limiting toxicity of chemotherapy, often requiring prolonged hospitalization and broad-spectrum antibiotic use. These can prompt dose reductions or treatment delays in subsequent chemotherapy cycles and compromise clinical outcome. A review by Dale et al. (2002) showed that about 25% to 40% of treatment-na&amp;iuml;ve patients develop FN with common chemotherapy regimens. Development of FN increases diagnostic and treatment costs and often leads to longer hospital stays. In addition, correlations have been reported between changes in neutrophil counts and quality of life, as measured by physical functioning, vitality, and mental health (Schnipper et al., 2012).</p>
<p><em>Statement from the American Society of Hematology (ASH) Lymphoma Task Force on gap</em>: <br />
This measure has been in use for the American Board of Internal Medicine (ABIM) Maintenance of Certification Performance Improvement Module since July 2013. Performance over the first 10 months (through May 2014) among this highly select group of hematologists is 82%. We believe performance among all hematologists would be somewhat lower. Due to the significant morbidity and costs associated with neutropenia, we suggest this gap remains significant.</p></div>"/>
    </field>
    <field fieldid="3502" ordby="170" id="576" name="Evidence for Additional Information Supporting Need for the Measure" type="citation">
      <fieldvalue value="<table><tr><td>American Society of Hematology (ASH). Non-Hodgkin lymphoma measure set: measure specifications. Washington (DC): American Society of Hematology (ASH); 2017 Feb. 36 p. </td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs. 2002;62 Suppl 1:1-15. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12479591&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
      <fieldvalue value="<table><tr><td>Schnipper LE, Smith TJ, Raghavan D, Blayney DW, Ganz PA, Mulvey TM, Wollins DS. American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol. 2012 May 10;30(14):1715-24. <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22493340&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
    </field>
    <field fieldid="3072" ordby="180" id="577" name="Extent of Measure Testing" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The non-Hodgkin lymphoma (NHL) measure set was developed by the American Society of Hematology (ASH) using a rigorous methodology (adapted from the American Medical Association [AMA]-convened Physician Consortium for Performance Improvement [PCPI]) and has been field tested. The NHL measure set was accepted by American Board of Internal Medicine (ABIM) for use with practice improvement modules meeting Part 4 of Maintenance of Certification Requirements in 2013.</p></div>"/>
    </field>
    <field fieldid="3007" ordby="190" id="578" name="Evidence for Extent of Measure Testing" type="citation">
      <fieldvalue value="<table><tr><td>Frechette S. (Principal, Northfield Associates, LLC, Warren, VT). Personal communication. 2014 Dec 10. &amp;nbsp;1 p. </td></tr></table>"/>
    </field>
  </section>
  <section secid="580" ordby="210" name="State of Use of the Measure">
    <field fieldid="3029" ordby="220" id="581" name="State of Use" type="picklist-one">
      <fieldvalue value="Current routine use"/>
    </field>
    <field fieldid="3030" ordby="230" id="582" name="Current Use" type="picklist-choice-3">
      <fieldvalue value="not defined yet"/>
    </field>
  </section>
  <section secid="583" ordby="240" name="Application of the Measure in its Current Use">
    <field fieldid="3031" ordby="250" id="584" name="Measurement Setting" type="picklist-choice">
      <fieldvalue value="Ambulatory/Office-based Care"/>
    </field>
    <field fieldid="3032" ordby="260" id="585" name="Professionals Involved in Delivery of Health Services" type="picklist-choice-3">
      <fieldvalue value="not defined yet"/>
    </field>
    <field fieldid="3033" ordby="270" id="586" name="Least Aggregated Level of Services Delivery Addressed" type="picklist-one">
      <fieldvalue value="Individual Clinicians or Public Health Professionals"/>
    </field>
    <field fieldid="3505" ordby="280" id="587" name="Statement of Acceptable Minimum Sample Size" type="picklist-one">
      <fieldvalue value="Unspecified"/>
    </field>
    <field fieldid="41" ordby="290" id="588" name="Target Population Age" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Age greater than or equal to 65 years</p></div>"/>
    </field>
    <field fieldid="42" ordby="300" id="589" name="Target Population Gender" type="picklist-one">
      <fieldvalue value="Either male or female"/>
    </field>
  </section>
  <section secid="660" ordby="310" name="National Strategy for Quality Improvement in Health Care">
    <field fieldid="3522" ordby="320" id="661" name="National Quality Strategy Aim" type="text">
      <fieldvalue value="<ul><li>Better Care</li></ul>"/>
    </field>
    <field fieldid="3525" ordby="330" id="662" name="National Quality Strategy Priority" type="text">
      <fieldvalue value="<ul><li>Prevention and Treatment of Leading Causes of Mortality</li></ul>"/>
    </field>
  </section>
  <section secid="590" ordby="340" name="Institute of Medicine (IOM) National Health Care Quality Report Categories">
    <field fieldid="3163" ordby="350" id="591" name="IOM Care Need" type="picklist-choice">
      <fieldvalue value="Living with Illness"/>
    </field>
    <field fieldid="3164" ordby="360" id="592" name="IOM Domain" type="picklist-choice">
      <fieldvalue value="Effectiveness"/>
    </field>
  </section>
  <section secid="593" ordby="370" name="Data Collection for the Measure">
    <field fieldid="3506" ordby="380" id="594" name="Case Finding Period" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Unspecified</p></div>"/>
    </field>
    <field fieldid="3054" ordby="390" id="595" name="Denominator Sampling Frame" type="picklist-one">
      <fieldvalue value="Patients associated with provider"/>
    </field>
    <field fieldid="3057" ordby="400" id="598" name="Denominator (Index) Event or Characteristic" type="picklist-choice">
      <fieldvalue value="Clinical Condition"/>
      <fieldvalue value="Patient/Individual (Consumer) Characteristic"/>
      <fieldvalue value="Therapeutic Intervention"/>
    </field>
    <field fieldid="3058" ordby="410" id="599" name="Denominator Time Window" type="picklist-choice-3">
      <fieldvalue value="not defined yet"/>
    </field>
    <field fieldid="55" ordby="420" id="596" name="Denominator Inclusions/Exclusions" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Inclusions</strong><br />
The number of lymphoma patients in your selection:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Who are greater than or equal to 65 years old
    <p>AND</p>
    </li>
    <li>Treated with CHOP +/-R (or any regimen with the same or higher doses of cyclophosphamide and doxorubicin and, thus, with an equivalent or higher potential for neutropenia) </li>
</ul>
<p class=&quot;Note&quot;><strong>Note</strong>: Refer to the original measure documentation for a list of International Classification of Diseases, Tenth Revision (ICD-10) codes used in lymphoma patient selection.</p>
<p><strong>Exclusions</strong><br />
None</p></div>"/>
    </field>
    <field fieldid="3507" ordby="430" id="597" name="Exclusions/Exceptions" type="picklist-choice-4">
      <fieldvalue value="not defined yet"/>
    </field>
    <field fieldid="59" ordby="440" id="600" name="Numerator Inclusions/Exclusions" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Inclusions</strong><br />
The number of lymphoma patients in your selection:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Who are greater than or equal to 65 years old
    <p>AND</p>
    </li>
    <li>Treated with CHOP +/-R (or any regimen with the same or higher doses of cyclophosphamide and doxorubicin and, thus, with an equivalent or higher potential for neutropenia)
    <p>AND</p>
    </li>
    <li>Received prophylactic filgrastim, filgrastim-sndz, tbo-filgrastim or pegfilgrastim </li>
</ul>
<p class=&quot;Note&quot;><strong>Note</strong>: This requires documentation in the patient medical record that the patient was 65 years of age or older AND treated with CHOP +/-R (or any regimen with the same or higher doses of cyclophosphamide and doxorubicin and, thus, with an equivalent or higher potential for neutropenia) AND that prophylactic filgrastim, filgrastim-sndz, tbo-filgrastim or pegfilgrastim were prescribed as recommended in the National Comprehensive Cancer Network (NCCN) guidelines. </p>
<p><strong>Exclusions</strong><br />
None</p></div>"/>
    </field>
    <field fieldid="3061" ordby="450" id="601" name="Numerator Search Strategy" type="picklist-one">
      <fieldvalue value="Fixed time period or point in time"/>
    </field>
    <field fieldid="3062" ordby="460" id="602" name="Data Source" type="picklist-many">
      <fieldvalue value="Administrative clinical data"/>
      <fieldvalue value="Paper medical record"/>
    </field>
    <field fieldid="3065" ordby="470" id="603" name="Type of Health State" type="picklist-one">
      <fieldvalue value="Does not apply to this measure"/>
    </field>
    <field fieldid="3066" ordby="480" id="604" name="Instruments Used and/or Associated with the Measure" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Unspecified</p></div>"/>
    </field>
  </section>
  <section secid="605" ordby="490" name="Computation of the Measure">
    <field fieldid="3508" ordby="500" id="606" name="Measure Specifies Disaggregation" type="picklist-one">
      <fieldvalue value="Does not apply to this measure"/>
    </field>
    <field fieldid="3067" ordby="520" id="608" name="Scoring" type="picklist-many">
      <fieldvalue value="Rate/Proportion"/>
    </field>
    <field fieldid="3068" ordby="530" id="609" name="Interpretation of Score" type="picklist-one">
      <fieldvalue value="Desired value is a higher score"/>
    </field>
    <field fieldid="3090" ordby="540" id="610" name="Allowance for Patient or Population Factors" type="picklist-choice-3">
      <fieldvalue value="not defined yet"/>
    </field>
    <field fieldid="3070" ordby="560" id="612" name="Standard of Comparison" type="picklist-choice-3">
      <fieldvalue value="not defined yet"/>
    </field>
  </section>
  <section secid="615" ordby="590" name="Identifying Information">
    <field fieldid="73" ordby="600" id="616" name="Original Title" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Measure 4: the percent of lymphoma patients that are 65 years old or older and receiving CHOP +/-R (or any regimen with the same or higher doses of cyclophosphamide and doxorubicin and, thus, with an equivalent or higher potential for neutropenia), prescribed prophylactic myeloid growth factor  (MGF) (filgrastim, filgrastim-sndz, tbo-filgrastim or pegfilgrastim).</p></div>"/>
    </field>
    <field fieldid="74" ordby="610" id="617" name="Measure Collection Name" type="text">
      <fieldvalue value="Non-Hodgkin Lymphoma Measure Set"/>
    </field>
    <field fieldid="16" ordby="650" id="621" name="Submitter" type="orglist">
      <fieldvalue value="American Society of Hematology - Medical Specialty Society"/>
    </field>
    <field fieldid="17" ordby="660" id="622" name="Developer" type="orglist-p">
      <fieldvalue value="American Society of Hematology - Medical Specialty Society"/>
    </field>
    <field fieldid="79" ordby="670" id="623" name="Funding Source(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The American Society of Hematology </p></div>"/>
    </field>
    <field fieldid="80" ordby="680" id="624" name="Composition of the Group that Developed the Measure" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The American Society of Hematology (ASH) Lymphoma Task Force:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Joseph Connors, MD (<em>Co-Chair</em>) </li>
    <li>Jane Winter, MD (<em>Co-Chair</em>) </li>
    <li>Jonathan Friedberg, MD, MMSc </li>
    <li>Mikkael Sekeres, MD, MS </li>
    <li>Lawrence A. Solberg, Jr., MD, PhD </li>
    <li>Karen Kayoumi (ASH) </li>
    <li>Charles Clayton (ASH) </li>
    <li>Suzanne Leous (ASH) </li>
    <li>Sue Frechette, RN, MBA (Northfield Associates LLC) </li>
    <li>Debra Reis (Healthmonix) </li>
    <li>Lauren Patrick (Healthmonix) </li>
</ul></div>"/>
    </field>
    <field fieldid="81" ordby="690" id="625" name="Financial Disclosures/Other Potential Conflicts of Interest" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Unspecified</p></div>"/>
    </field>
    <field fieldid="19" ordby="730" id="629" name="Adaptation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This measure was not adapted from another source.</p></div>"/>
    </field>
    <field fieldid="3086" ordby="740" id="630" name="Date of Most Current Version in NQMC" type="date">
      <fieldvalue value="2017 Feb"/>
    </field>
    <field fieldid="3511" ordby="750" id="631" name="Measure Maintenance" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>American Society of Hematology (ASH) reviews/updates measures annually</p></div>"/>
    </field>
    <field fieldid="3512" ordby="760" id="632" name="Date of Next Anticipated Revision" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Unspecified</p></div>"/>
    </field>
    <field fieldid="20" ordby="770" id="633" name="Measure Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the measure.</p>
<p>This measure updates a previous version: American Society of Hematology (ASH). Non-Hodgkin lymphoma measure set: measure specifications. Washington (DC): American Society of Hematology (ASH); 2015 Dec. 36 p. </p></div>"/>
    </field>
    <field fieldid="14" ordby="780" id="634" name="Measure Availability" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Source not available electronically. </p>
<p>For more information, contact the American Society of Hematology (ASH) at 2021 L Street NW, Suite 900, Washington, DC 20036; Phone: 202-776-0544; Fax: 202-776-0545; Web site: <a href=&quot;http://www.hematology.org/&quot; title=&quot;ASH Web site&quot;>www.hematology.org</a>. </p></div>"/>
    </field>
    <field fieldid="87" ordby="800" id="636" name="NQMC Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NQMC summary was completed by ECRI Institute on June 19, 2015. The information was verified by the measure developer on August 27, 2015. </p>
<p>This NQMC summary was updated by ECRI Institute on April 18, 2016. The information was verified by the measure developer on May 24, 2016. </p>
<p>This NQMC summary was updated again by ECRI Institute on March 21, 2017. The information was verified by the measure developer on May 3, 2017.</p></div>"/>
    </field>
    <field fieldid="88" ordby="810" id="637" name="Copyright Statement" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NQMC summary is based on the original measure, which is subject to the measure developer's copyright restrictions.</p>
<p>For more information, contact Robert M. Plovnick, MD, MS, Director of Quality Improvement Programs at the American Society of Hematology (ASH), 2021 L Street NW, Suite 900, Washington, DC 20036.</p></div>"/>
    </field>
  </section>
  <section secid="641" ordby="850" name="Production">
    <field fieldid="1" ordby="1366" id="562" name="Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>American Society of Hematology (ASH). Non-Hodgkin lymphoma measure set: measure specifications. Washington (DC): American Society of Hematology (ASH); 2017 Feb. 36 p. </td></tr></table>"/>
    </field>
  </section>
  <section secid="99999" ordby="99999" name="Disclaimer">
    <field fieldid="99999" ordby="99999" id="99999" name="NQMC Disclaimer" type="text">
      <fieldvalue value="<p>The National Quality Measures Clearinghouseâ„¢ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.</p> 
<p>All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.</p> 
<p>Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the <a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;>NQMC Inclusion Criteria</a>.</p> 
<p>NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding measure content are directed to contact the measure developer.</p>"/>
    </field>
  </section>
</version><!--
     FILE ARCHIVED ON 06:09:20 Jun 21, 2018 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 01:00:32 Jul 16, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 532.423 (3)
  esindex: 0.006
  captures_list: 555.91
  CDXLines.iter: 13.067 (3)
  PetaboxLoader3.datanode: 57.017 (4)
  exclusion.robots: 0.174
  exclusion.robots.policy: 0.161
  RedisCDXSource: 7.544
  PetaboxLoader3.resolve: 606.65 (2)
  load_resource: 191.854
-->